Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR5A2 | O00482 | 1/20 | 1.00 |
| ▸ | NR5A1 | Q13285 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | FABP3 | P05413 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | PTAFR | P25105 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimyristoylphosphatidylcholine SCHEMBL244839 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL10498112 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL37475 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234790 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233046 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL22693933 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL236969 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL231824 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL2036043 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL24563 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 630 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12589078-B2 | Lipid nanoparticles for delivery of nucleic acids | CureVac SE (DE) | 2026-03-31 | — | — | US | claimed |
| US-12576037-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4106828-B1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL INC (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260053750-A1 | INHALABLE COMPOSITIONS OF CDK9 INHIBITORS | OWEN MATTHEW (US) | 2026-02-26 | — | — | US | claimed |
| EP-4678198-A2 | POLYMER-ENCAPSULATED DRUG PARTICLES | Tonic Medical, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4572804-A2 | INHALABLE COMPOSITIONS OF CDK9 INHIBITORS | The Regents of the University of California (US) | 2025-06-25 | — | — | EP | claimed |
| US-12226740-B2 | Stabilized filtration device | RETEIN AB (SE) | 2025-02-18 | — | — | US | claimed |
| US-20240398940-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2024-12-05 | — | — | US | claimed |
| US-20240315976-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL, INC. | 2024-09-26 | — | — | US | claimed |
| US-20220152559-A1 | STABILIZED FILTRATION DEVICE | RETEIN AB (SE) | 2022-05-19 | — | — | US | claimed |
| WO-2020241925-A1 | LIPID NANOPARTICLE COMPLEX CAPTURING APTIDE FUSED WITH CELL-PENETRATING MATERIAL AND USE THEREOF | 한국과학기술원 | 2020-12-03 | — | — | WO | claimed |
| US-20200376138-A1 | LIPID NANO PARTICLE COMPLEX COMPRISING APTIDE FUSED WITH CELL PENETRATING MATERIALS AND USE SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-03 | — | — | US | claimed |
| EP-3684180-A1 | NOVEL THERAPIES FOR TREATING AND PREVENTING CHRONIC RHINOSINUSITIS | The Scripps Research Institute (US) | 2020-07-29 | — | — | EP | claimed |
| WO-2019060761-A1 | NOVEL THERAPIES FOR TREATING AND PREVENTING CHRONIC RHINOSINUSITIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-03-28 | — | — | WO | claimed |
| US-20170067904-A1 | COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DETERGENT STABILITY SCREEN | UNIV VIRGINIA PATENT FOUNDATION (US) | 2017-03-09 | — | — | US | claimed |
| US-20120108463-A1 | COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DETERGENT STABILITY SCREEN | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-03 | — | — | US | claimed |
| US-7829684-B2 | Methods for producing soluble membrane-spanning proteins | GENENTECH, INC. (US) | 2010-11-09 | — | — | US | claimed |
| US-20080160313-A1 | Lipid bilayers on nanotextured solid surfaces | ENERGY, U.S. DEPARTMENT OF | 2008-07-03 | — | — | US | claimed |
| US-20030134420-A1 | Methods and compositions for gene delivery | IMMUNE RESPONSE CORPORATION, THE | 2003-07-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053750-A1 | INHALABLE COMPOSITIONS OF CDK9 INHIBITORS | CDK9, CDK19, CDK5 | SMN1; SMN2 2764/4885NR5A2 4594/4885NR5A1 3796/4885 |
| US-12576037-B2 | Polymer-encapsulated drug particles | PHOSPHO1, SGMS1, SGMS2 | SMN1; SMN2 578/4885NR5A2 3443/4885NR5A1 3606/4885 |
| US-12589078-B2 | Lipid nanoparticles for delivery of nucleic acids | STARD3, PCTP, EXOSC10 | SMN1; SMN2 2059/4885NR5A2 1289/4885NR5A1 344/4885 |
| US-20240398940-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | ABHD16A, FASN, PHAX | SMN1; SMN2 2758/4885NR5A2 3252/4885NR5A1 3492/4885 |
| US-20030134420-A1 | Methods and compositions for gene delivery | POLRMT, NUP205, POLM | SMN1; SMN2 204/4885NR5A2 3716/4885NR5A1 4533/4885 |
| US-20240315976-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | CD47, GRPR, HSPA5 | SMN1; SMN2 468/4885NR5A2 2470/4885NR5A1 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.